Craigakess, As you're at 0.86, you know that th

Craigakess,

As you're at 0.86, you know that the HIV indication, while painfully late for all who are here pre-covid, really provides a nearly unassailable backstop to your investment.

That certainty, that leronlimab crushes maraviroc and other anti-virals in HIV, was a large part of my pitch of Cytodyn to my brother and his wife.

I started following Cytodyn with the emergence of Covid, after EINDS and Patterson paper, long before I knew of ohm20 and the absurd bounty of indications leronlimab should address.

I've sold EXAS, HGEN, FATE, ESPR,SYGHH and ETSY to buy Cytodyn. Were it not for leronlimab, I would still be invested in all of these at one level or another.

Obviously I'm a fan of the science and was formerly an adherent to diversification, but this is not an opportunity I could walk past.

If a black hole warps reality and the rule of science change, I'll be working a few more years than I planned. If science holds, I'll be retiring much earlier than I previously imagined.